Cargando…

(18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with (68)Ga-labeled compounds has rapidly become adopted as part of routine clinical care in many parts of the world. However, recent years have witnessed the start of a shift from (68)Ga- to (18)F-labeled PSMA-target...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werner, Rudolf A., Derlin, Thorsten, Lapa, Constantin, Sheikbahaei, Sara, Higuchi, Takahiro, Giesel, Frederik L., Behr, Spencer, Drzezga, Alexander, Kimura, Hiroyuki, Buck, Andreas K., Bengel, Frank M., Pomper, Martin G., Gorin, Michael A., Rowe, Steven P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929634/ https://www.ncbi.nlm.nih.gov/pubmed/31903102 http://dx.doi.org/10.7150/thno.37894

Ejemplares similares

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
por: Werner, Rudolf A., et al.
Publicado: (2019)

The next era of renal radionuclide imaging: novel PET radiotracers
por: Werner, Rudolf A., et al.
Publicado: (2019)

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications
por: Werner, Rudolf A., et al.
Publicado: (2018)

Recent advances in radiotracers targeting norepinephrine transporter: structural development and radiolabeling improvements
por: Chen, Xinyu, et al.
Publicado: (2020)

Lewis Acid-Facilitated Radiofluorination of MN3PU: A LRRK2 Radiotracer
por: Malik, Noeen, et al.
Publicado: (2020)

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov
por: Zippel, Claus, et al.
Publicado: (2020)

Strained Ammonium Precursors for Radiofluorinations
por: Reissig, Falco, et al.
Publicado: (2022)

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia
por: Werner, Rudolf A., et al.
Publicado: (2017)

Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating
por: Rowe, Steven P., et al.
Publicado: (2020)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers
por: Weich, Alexander, et al.
Publicado: (2022)

Ventricular Distribution Pattern of the Novel Sympathetic Nerve PET Radiotracer (18)F-LMI1195 in Rabbit Hearts
por: Werner, Rudolf A., et al.
Publicado: (2019)

Rationalizing the Binding Modes of PET Radiotracers Targeting the Norepinephrine Transporter
por: Tutov, Anna, et al.
Publicado: (2023)

A Voice From the Past: Rediscovering the Virchow Node With Prostate-specific Membrane Antigen-targeted (18)F-DCFPyL Positron Emission Tomography Imaging
por: Werner, Rudolf A., et al.
Publicado: (2018)

Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
por: Giglio, Javier, et al.
Publicado: (2018)

Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer
por: Khatri, Wajahat, et al.
Publicado: (2021)

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
por: Loktev, Anastasia, et al.
Publicado: (2019)

PSMA Theranostics: Science and Practice
por: Mokoala, Kgomotso, et al.
Publicado: (2021)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
por: Leung, Kevin H., et al.
Publicado: (2022)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
por: Lundmark, Fanny, et al.
Publicado: (2020)

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2022)

Procedures for the GMP-Compliant Production and Quality Control of [(18)F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
por: Cardinale, Jens, et al.
Publicado: (2017)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

(64)Cu-DOTHA(2)-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
por: Milot, Marie-Christine, et al.
Publicado: (2022)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Radiofluorination using aluminum-fluoride (Al(18)F)
por: McBride, William J, et al.
Publicado: (2013)

Copper-Mediated Radiofluorination of Arylstannanes with [(18)F]KF
por: Makaravage, Katarina J., et al.
Publicado: (2016)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

(177)Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With (177)Lu-PSMA-I&T
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
por: Henkenberens, Christoph, et al.
Publicado: (2020)

Uptake of [(18)F]DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in the Clinical Interpretation of PSMA PET Studies
por: Rowe, Steven P., et al.
Publicado: (2015)

(177)Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
por: Sadaghiani, Mohammad S., et al.
Publicado: (2022)

Uptake of Prostate-Specific Membrane Antigen (PSMA) in adenoid cystic carcinoma – Is PSMA-PET-CT a helpful tool in radiation oncology?
por: König, Laila, et al.
Publicado: (2017)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_debp2d8eeqta2gue7s6kh6djfa